Mackenzie Financial Corp Grows Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Mackenzie Financial Corp lifted its holdings in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 499.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 299,815 shares of the company's stock after acquiring an additional 249,765 shares during the quarter. Mackenzie Financial Corp owned 0.13% of Gossamer Bio worth $271,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in GOSS. Graham Capital Management L.P. purchased a new position in Gossamer Bio in the 4th quarter worth $32,000. Fullcircle Wealth LLC bought a new position in shares of Gossamer Bio during the fourth quarter valued at about $43,000. Velan Capital Investment Management LP purchased a new stake in Gossamer Bio during the 4th quarter valued at about $68,000. Bank of America Corp DE grew its position in Gossamer Bio by 107.2% during the 4th quarter. Bank of America Corp DE now owns 84,788 shares of the company's stock worth $77,000 after acquiring an additional 43,866 shares during the last quarter. Finally, Jefferies Financial Group Inc. purchased a new position in Gossamer Bio in the 4th quarter worth approximately $90,000. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Trading Up 5.6%

Shares of GOSS stock traded up $0.07 during trading hours on Friday, reaching $1.33. The company's stock had a trading volume of 1,427,482 shares, compared to its average volume of 1,553,217. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio, Inc. has a one year low of $0.50 and a one year high of $1.55. The stock has a market capitalization of $302.31 million, a P/E ratio of -4.16 and a beta of 1.85. The firm's fifty day simple moving average is $1.01 and its 200 day simple moving average is $1.02.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The business had revenue of $9.89 million during the quarter, compared to analysts' expectations of $3.95 million. Equities research analysts expect that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Wall Street Analyst Weigh In

GOSS has been the subject of a number of analyst reports. The Goldman Sachs Group increased their price objective on Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, May 16th. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Gossamer Bio in a report on Tuesday, March 18th. Finally, Wedbush reissued an "outperform" rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Friday, May 16th.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.